Forty Seven

Forty Seven is a clinical-stage immuno-oncology company located in Menlo Park, California, focusing on developing therapies that activate macrophages to fight cancer. The company’s lead program, 5F9, is a monoclonal antibody targeting the CD47 receptor, a “don’t eat me” signal that allows cancer cells to actively avoid being engulfed by macrophages. This antibody is currently being evaluated in multiple clinical studies involving patients with solid tumors, myelodysplastic syndromes, acute myeloid leukemia, non-Hodgkin lymphoma, ovarian cancer, and colorectal cancer.